Adapted from Papp K, et al. 2021.
aPrimary psoriasis safety pool includes NCT02054481, UltIMMA-1, UltIMMa-2, IMMhance (NCT02672852), and IMMvent.
bDue to natural causes (n = 1), car accident (n = 1), cardiopulmonary arrest (n = 1), cause unknown (n = 2), COVID-19 (n = 1); none determined by the investigator to be related to Skyrizi.
cMACE rate in the LIMMitless study is consistent with the incidence rate of MACE in the Psoriasis Longitudinal Assessment and Registry (PSOLAR; 0.57 events/100 PYs; 95% CI, 0.50–0.65)
dSerious hypersensitivity reactions (none of which were determined by the investigator to be related to Skyrizi) were paraphenylenediamine allergy (n = 1; mild, attributed to hair dye application), generalized microbial eczema (n = 1; moderate, attributed to prolonged duration of generalized eczema and lack of response to treatment with hydrocortisone), and Stevens-Johnson syndrome (n = 1; severe, attributed to addition of chlorpromazine).
AE, adverse event; MACE, major adverse cardiovascular event; NMSC, non-melanoma skin cancer; PYs, patient years; RZB, risankizumab; TEAEs, treatment-emergent adverse events.